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Abstract
There is tremendous interest in precision medicine as a means to im-
prove patient outcomes by tailoring treatment to individual characteristics.
An individualized treatment rule formalizes precision medicine as a map
from patient information to a recommended treatment. A treatment rule
is defined to be optimal if it maximizes the mean of a scalar outcome in
a population of interest, e.g., symptom reduction. However, clinical and
intervention scientists often must balance multiple and possibly compet-
ing outcomes, e.g., symptom reduction and the risk of an adverse event.
One approach to precision medicine in this setting is to elicit a composite
outcome which balances all competing outcomes; unfortunately, eliciting a
composite outcome directly from patients is difficult without a high-quality
instrument, and an expert-derived composite outcome may not account for
heterogeneity in patient preferences. We propose a new paradigm for the
study of precision medicine using observational data that relies solely on
the assumption that clinicians are approximately (i.e., imperfectly) mak-
ing decisions to maximize individual patient utility. Estimated composite
outcomes are subsequently used to construct an estimator of an individual-
ized treatment rule which maximizes the mean of patient-specific composite
outcomes. The estimated composite outcomes and estimated optimal indi-
vidualized treatment rule provide new insights into patient preference het-
erogeneity, clinician behavior, and the value of precision medicine in a given
domain. We derive inference procedures for the proposed estimators under
mild conditions and demonstrate their finite sample performance through a
suite of simulation experiments and an illustrative application to data from
a study of bipolar depression.
Keywords: Individualized treatment rules; Inverse reinforcement learning; Preci-
sion medicine; Utility functions
1 Introduction
Precision medicine is an approach to healthcare that involves tailoring treatment
based on individual patient characteristics (Hamburg and Collins, 2010; Collins and Varmus,
2015). Accounting for heterogeneity by tailoring treatment has the potential to
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improve patient outcomes in many therapeutic areas. An individualized treatment
rule formalizes precision medicine as a map from the space of patient covariates
into the space of allowable treatments (Murphy, 2003; Robins, 2004). Almost
all methods for estimating individualized treatment rules have been designed to
optimize a scalar outcome (exceptions will be discussed shortly). However, in
practice, clinical decision making often requires balancing trade-offs between mul-
tiple outcomes. For example, clinicians treating patients with bipolar disorder
must manage both depression and mania. Antidepressants may help correct de-
pressive episodes but may also induce manic episodes (Sachs et al., 2007; Ghaemi,
2008; Goldberg, 2008; Wu et al., 2015). We propose a novel framework for using
observational data to estimate a composite outcome and the associated optimal
individualized treatment rule.
The estimation of optimal individualized treatment rules has been studied
extensively, leading to a wide range of estimators. These estimators include:
regression-based methods like Q-learning (Murphy, 2005; Qian and Murphy, 2011;
Schulte et al., 2014; Laber et al., 2014), A-learning (Murphy, 2003; Robins, 2004;
Blatt et al., 2004; Moodie et al., 2007; Wallace and Moodie, 2015), and regret re-
gression (Henderson et al., 2010); direct-search methods (Rubin and van der Laan,
2012; Zhang et al., 2012; Zhao et al., 2012; Zhang et al., 2013; Zhou et al., 2017)
based on inverse probability weighting (Robins, 1999; Murphy et al., 2001; van der Laan and Petersen,
2007; Robins et al., 2008); and hybrid methods (Taylor et al., 2015; Zhang et al.,
2017). The preceding methods require specification of a single scalar outcome
that will be used to define an optimal regime; were individual patient utilities
known, then they could be used as the outcome in any of these methods. How-
ever, in general such utilities are not known though they can be elicited provided
a high-quality instrument is available (Butler et al., 2017); in the absence of such
an instrument, preference elicitation is difficult to apply.
We propose a new paradigm for estimating optimal individualized treatment
rules from observational data without eliciting patient preferences. The key premise
is that clinicians are attempting to act optimally with respect to each patient’s
utility and thus the observed treatment decisions contain information about indi-
vidual patient utilities. This idea is similar to that introduced by Wallace et al.
(2018) (see also Wallace et al., 2016); however, we provide an estimator for the
probability that a patient is treated optimally, rather than assuming that all pa-
tients are treated optimally. We construct estimators of individual patient utilities
which do not require that clinicians are acting optimally, only that they approxi-
mately follow an optimal policy. This approach allows us to describe the goals of
the decision maker and how these goals vary across patients, determine what makes
a patient more or less likely to be treated optimally under standard care, and es-
timate the decision rule which optimizes patient-specific composite outcomes. We
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develop this approach in the context of a single-stage, binary decision in the pres-
ence of two outcomes. An extension to the setting with more than two outcomes
is discussed in the Appendix.
Other methods for estimating individualized treatment rules in the presence
of multiple outcomes include using an expert-derived composite outcome for all
patients (Thall et al., 2002, 2007). However, this does not account for differences
in the utility function across patients and in some cases it may not be possible
to elicit a high-quality composite outcome from an expert. Alternatively, multiple
outcomes can be incorporated using set-valued treatment regimes (Laber et al.,
2014; Lizotte and Laber, 2016; Wu, 2016), constrained optimization (Linn et al.,
2015; Laber et al., 2016), or inverse preference elicitation (Lizotte et al., 2012).
Schnell et al. (2017) extend methods for estimating the benefiting subgroup to the
case of multiple outcomes using the concept of admissibility (see also Schnell et al.,
2016). However, none of these approaches provide a method for estimating an
individual patient’s utility.
This work is closely related to inverse reinforcement learning (Kalman, 1964;
Ng et al., 2000; Abbeel and Ng, 2004; Ratliff et al., 2006), which involves studying
decisions made by an expert and constructing the utility function that is optimized
by the expert’s decisions. Inverse reinforcement learning has been successfully ap-
plied in navigation (Ziebart et al., 2008) and human locomotion (Mombaur et al.,
2009). Inverse reinforcement learning methods assume that decisions are made in a
single environment. However, in the context of precision medicine, both the utility
function and the probability of optimal treatment may vary across patients. Our
approach is a version of inverse reinforcement learning with multiple environments.
In Section 2, we introduce a pseudo-likelihood method to estimate patient
utility functions from observational data. In Section 3, we state a number of
theoretical results pertaining to the proposed method, including consistency and
inference for the maximum pseudo-likelihood estimators. Section 4 presents a
series of simulation experiments used to evaluate the finite sample performance of
the proposed methods. Section 5 presents an illustrative application using data
from the STEP-BD bipolar disorder study. Conclusions and a discussion of future
research are given in Section 6. Proofs are given in the appendix along with
additional simulation results and a discussion of an extension to more than two
outcomes.
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2 Pseudo-likelihood Estimation of Utility Func-
tions
Assume the available data are (Xi, Ai, Yi, Zi), i = 1, . . . , n, which comprise n
independent and identically distributed copies of (X, A, Y, Z), where X ∈ X ⊆ Rp
are patient covariates, A ∈ A = {−1, 1} is a binary treatment, and Y and Z
are two real-valued outcomes for which higher values are more desirable. The
extension to scenarios with more than two outcomes is discussed in the Appendix.
An individualized treatment rule is a function d : X → A such that, under d, a
patient presenting with covariates X = x will be assigned to treatment d(x). Let
Y ∗(a) denote the potential outcome under treatment a ∈ A, and for any regime
d, define Y ∗(d) =
∑
a∈A Y
∗(a)1 {d(X) = a}. An optimal regime for the outcome
Y , say doptY , satisfies EY
∗
(
doptY
) ≥ EY ∗(d) for any other regime d. The optimal
regime for the outcome Z, say doptZ , is defined analogously. In order to identify
these optimal regimes, and subsequently to identify the optimal regime across the
class of utility functions introduced below, we make the following assumptions.
Assumption 1. Consistency, Y = Y ∗(A) and Z = Z∗(A).
Assumption 2. Positivity, Pr(A = a|X = x) ≥ c > 0 for some constant c and
all pairs (x, a) ∈ X ×A.
Assumption 3. Ignorability, {Y ∗(−1), Y ∗(1)}⊥A |X and {Z∗(−1), Z∗(1)}⊥A |X.
These assumptions are standard in causal inference (Robins, 2004; Hernan and Robins,
2010). Assumption 3 is not empirically verifiable in observational studies (Rosenbaum and Rubin,
1983; Rosenbaum, 1984).
Define QY (x, a) = E (Y |X = x, A = a). Then, under the preceding assump-
tions, it can be shown that doptY (x) = argmaxa∈AQY (x, a) (Zhang et al., 2012).
Similarly, it follows that doptZ (x) = argmaxa∈AQZ(x, a) whereQZ(x, a) = E (Z|X = x, A = a).
In general, doptY (x) need not equal d
opt
Z (x); therefore, if both Y and Z are clinically
relevant, neither doptY nor d
opt
Z may be acceptable. We assume that there exists
an unknown and possibly covariate-dependent utility U = u(Y, Z), where u :
R2 → R measures the “goodness” of the outcome pair (y, z). The optimal regime
with respect to U , say doptU , satisfies EU
∗
(
doptU
)
= Eu
{
Y ∗
(
doptU
)
, Z∗
(
doptU
)} ≥
Eu {Y ∗(d), Z∗(d)} = EU∗(d) for any other regime d. The goal is to use the ob-
served data to estimate the utility and subsequently doptU . Define QU(x, a) =
E(U |X = x, A = a). For the class of utility functions we consider below, QU (x, a)
is a (possibly covariate-dependent) convex combination of QY (x, a) and QZ(x, a)
and is therefore identifiable under the stated causal assumptions and furthermore
doptU (x) = argmaxa∈AQU(x, a).
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We assume that clinicians act with the goal of optimizing each patient’s utility
and that their success in identifying the optimal treatment depends on individual
patient characteristics. Therefore, we assume that the clinicians are approximately,
i.e., imperfectly, assigning treatment according to doptU (x). If the clinician were
always able to correctly identify the optimal treatment and assign A = doptU (X)
for each patient, there would be no need to estimate the optimal treatment policy
(Wallace et al., 2016). Instead, we assume that the decisions of the clinician are
imperfect and that Pr
{
A = doptU (x)|X = x
}
= expit (x⊺β) where β is an unknown
parameter. We implicitly assume throughout that X may contain higher order
terms, interactions, or basis functions constructed from the covariates.
2.1 Fixed Utility
We begin by assuming that the utility function is constant across patients and
takes the form u(y, z;ω) = ωy + (1 − ω)z for some ω ∈ [0, 1]. Lemma 1 of
Butler et al. (2017) states that, for a broad class of utility functions, the optimal
individualized treatment rule is equivalent to the optimal rule for a utility function
of this form. Define Qω(x, a) = ωQY (x, a) + (1− ω)QZ(x, a) and define doptω (x) =
argmaxa∈AQω(x, a). Let Q̂Y,n and Q̂Z,n denote estimators of QY and QZ obtained
from regression models fit to the observed data (Qian and Murphy, 2011). For a
fixed value of ω, let Q̂ω,n(x, a) = ωQ̂Y,n(x, a)+ (1−ω)Q̂Z,n(x, a) and subsequently
let d̂ω,n(x) = argmaxa∈AQ̂ω,n(x, a) be the plug-in estimator of d
opt
ω (x). Given Q̂Y,n
and Q̂Z,n, d̂ω,n(x) can be computed for each ω ∈ [0, 1].
The joint distribution of (X, A, Y, Z) is
f(X, A, Y, Z) = f(Y, Z|X, A)f(A|X)f(X)
= f(Y, Z|X, A)f(X)exp [X
⊺β1 {A = doptω (X)}]
1 + exp (X⊺β)
.
Assuming that f(Y, Z|X, A) and f(X) do not depend on ω or β, the likelihood for
(ω, β) is
Ln(ω, β) ∝
n∏
i=1
exp [X⊺i β1 {Ai = doptω (Xi)}]
1 + exp (X⊺i β)
, (1)
which depends on the unknown function doptω . Plugging in d̂ω,n for d
opt
ω into (1)
yields the pseudo-likelihood
L̂n(ω, β) ∝
n∏
i=1
exp
[
X
⊺
i β1
{
Ai = d̂ω,n(Xi)
}]
1 + exp (X⊺i β)
. (2)
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If we let ω̂n and β̂n denote the maximum pseudo-likelihood estimators obtained by
maximizing (2), then an estimator of the utility function is ûn(y, z) = u (y, z; ω̂n) =
ω̂ny+(1− ω̂n)z and expit
(
x⊺β̂n
)
is an estimator of the probability that a patient
presenting with covariates x would be treated optimally under standard care. An
estimator of the optimal policy at x is d̂ω̂n,n(x) = argmaxa∈AQ̂ω̂n,n(x, a).
Because the pseudo-likelihood given in (2) is non-smooth in ω, standard gradient-
based optimization algorithms cannot be used. However, for a given ω, it is
straightforward to compute the profile estimator β̂n(ω) = argmaxβ∈RpL̂n(ω, β).
We can compute the profile pseudo-likelihood estimator over a grid of values for
ω and select the point on the grid yielding the largest pseudo-likelihood. The
algorithm to construct
(
ω̂n, β̂n
)
is given in Algorithm 1 below. Step (3) can be
Algorithm 1: Pseudo-likelihood estimation of fixed utility function.
1 Set a grid 0 = ω0 < ω1 < . . . < ωK = 1;
2 for m = 0, . . . , K do
3 compute β̂n(ωn) = argmaxβ∈Rp L̂n(ωm, β) ;
4 end
5 Select m̂n = argmax0≤m≤KL̂n
{
ωm, β̂n(ωm)
}
;
6 Set
(
ω̂n, β̂n
)
=
{
ωm̂n, β̂n (ωm̂n)
}
;
accomplished using logistic regression. The theoretical properties of this estimator
are discussed in Section 3.
2.2 Patient-specific Utility
Outcome preferences can vary widely across patients in some application domains,
including schizophrenia (Kinter, 2009; Strauss et al., 2010) and pain management
(Gan et al., 2004). To accommodate this setting, we assume that the utility func-
tion takes the form u(y, z;x, ω) = ω(x)y + {1− ω(x)} z where ω : X → [0, 1]
is a smooth function. For illustration, we let ω(x; θ) = expit (x⊺θ) where θ
is an unknown parameter. The situation of a misspecified model for the util-
ity function is discussed in the Appendix. Define Qθ(x, a) = ω(x; θ)QY (x, a) +
{1− ω(x; θ)}QZ(x, a) and define doptθ (x) = argmaxa∈AQθ(x, a). Let Q̂Y,n and
Q̂Z,n denote estimators of QY and QZ obtained from regression models fit to
the observed data. For a fixed value of θ, let Q̂θ,n(x, a) = ω(x; θ)Q̂Y,n(x, a) +
{1− ω(x; θ)} Q̂Z,n(x, a) and subsequently let d̂θ,n(x) = argmaxa∈AQ̂θ,n(x, a) be
the plug-in estimator of doptθ (x). Assume that decisions are made according to
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the model Pr
{
A = doptθ (x)|X = x
}
= expit (x⊺β). We compute the estimators(
θ̂n, β̂n
)
of (θ, β) by maximizing the pseudo-likelihood
L̂n(θ, β) ∝
n∏
i=1
exp
[
X
⊺
i β1
{
Ai = d̂θ,n(Xi)
}]
1 + exp (X⊺i β)
. (3)
An estimator for the utility function is ûn(y, z;x) = ω
(
x; θ̂n
)
y+
{
1− ω
(
x; θ̂n
)}
z
and an estimator for the optimal decision function is d̂θ̂n,n.
As before, the pseudo-likelihood given in (3) is non-smooth in θ and standard
gradient-based optimization methods cannot be used. It is again straightforward
to compute the profile pseudo-likelihood estimator β̂n(θ) = argmaxβ∈RpL̂n(θ, β)
for any θ ∈ Rp. However, because it is computationally infeasible to compute β̂n(θ)
for all θ on a grid if θ is of moderate dimension, we generate a random walk through
the parameter space using the Metropolis algorithm as implemented in the metrop
function in the R package mcmc (Geyer and Johnson, 2017) and compute the profile
pseudo-likelihood for each θ on the random walk. Let L˜n(θ) = maxβ∈Rp L̂n(θ, β).
We can compute L˜n(θ) = L̂n
{
θ, β̂n(θ)
}
by estimating β̂n(θ) using logistic re-
gression as described in Section 2.1. The algorithm to construct a random walk
through the parameter space is given in Algorithm 2 below. After generating a
Algorithm 2: Pseudo-likelihood estimation of patient-dependent utility
function
1 Set a chain length, B, fix σ2 > 0, and initialize θ1 to a starting value in Rp;
2 for b = 2, . . . , B do
3 Generate e ∼ N(0, σ2I);
4 Set θ˜b+1 = θb + e;
5 Compute p = min
{
L˜n
(
θ˜b+1
)
/L˜n
(
θ˜b
)
, 1
}
;
6 Generate U ∼ U(0, 1); if U ≤ p, set θb+1 = θ˜b+1; otherwise, set θb+1 = θb;
7 end
chain (θ1, . . . , θB), we select the θk that leads to the largest value of L˜n(θk) as the
maximum pseudo-likelihood estimator. Standard practice is to choose the variance
of the proposal distribution, σ2, so that the acceptance proportion is between 0.25
and 0.5 (Geyer and Johnson, 2017).
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3 Theoretical Results
Here we state a number of theoretical results pertaining to the proposed pseudo-
likelihood estimation method for utility functions. We state results for a patient-
specific utility function; the setting where the utility function is fixed is a special
case. All proofs are deferred to the appendix.
We assume that Pr
{
A = doptU (x)|X = x
}
= expit(x⊺β0) and that the true util-
ity function is u(y, z;x, θ0) = ω (X; θ0) y + {1− ω (X; θ0)} z, where ω(X; θ) has
bounded continuous derivative on compact sets and doptθ0 (X) = d
opt
θ (X) almost
surely implies θ = θ0, i.e., the model introduced in Section 2.2 is well-defined
and correctly specified with true parameters β0 ∈ Rp and θ0 ∈ Rd. We further
assume that the estimators Q̂Y,n(x, a) and Q̂Z,n(x, a) are pointwise consistent for
all ordered pairs (x, a). Along with assumptions 1-3, we implicitly assume that
the densities f(Y, Z|X, A) and f(X) exist. The following result states the consis-
tency of the maximum pseudo-likelihood estimators for the utility function and
the probability of optimal treatment. The proof involves verifying the conditions
of Theorem 2.12 of Kosorok (2008).
Theorem 3.1 (Consistency with patient-specific utility). Let the maximum pseudo-
likelihood estimators be as in Section 2.2,
(
θ̂n, β̂n
)
= argmaxθ∈Rp,β∈BL̂n(θ, β).
Assume that B is a compact set with β0 ∈ B and that ‖EX‖ < ∞. Then,∥∥∥θ̂n − θ0∥∥∥ P−→ 0 and ∥∥∥β̂n − β0∥∥∥ P−→ 0 as n→∞.
Let Vθ(d) = E {u(Y, Z;X, θ)|A = d(X)} be the mean composite outcome in a
population where decisions are made according to d. The following result estab-
lishes the consistency of the value of the estimated optimal policy. The proof uses
general theory developed by Qian and Murphy (2011).
Theorem 3.2 (Value consistency with patient-specific utility). Let θ̂n be the max-
imum pseudo-likelihood estimator for θ and let d̂θ̂n,n be the associated estimated
optimal policy. Then, under the given assumptions,
∣∣∣Vθ0 (d̂θ̂n,n)− Vθ0 (doptθ0 )∣∣∣ P−→ 0
as n→∞.
Next, we derive the convergence rate and asymptotic distribution of
(
θ̂n, β̂n
)
.
Assume that X is a bounded subset of Rp and let ‖·‖X be the sup norm over X , i.e.,
for f : X → R, ‖f‖X = supx∈X |f(x)|. Let ω˙θ(x) = (∂/∂θ)ω(x; θ). Assume that∥∥‖ω˙θ0(x)‖∥∥X < ∞ and that limθ→θ0 ∥∥‖ω˙θ(x) − ω˙θ0(x)‖∥∥X = 0. Define RY (x) =
QY (x, 1)−QY (x,−1), RZ(x) = QZ(x, 1)−QZ(x,−1), andR0(x) = RY (x)−RZ(x).
Similarly, define R̂Y,n(x) = Q̂Y,n(x, 1) − Q̂Y,n(x,−1), R̂Z,n(x) = Q̂Z,n(x, 1) −
Q̂Z,n(x,−1), and R̂0,n(x) = R̂Y,n(x) − R̂Z,n(x). Let Dθ(x) = ω(x; θ)RY (x) +
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{1− ω(x; θ)}RZ(x) and D̂θ,n(x) = ω(x; θ)R̂Y,n(x) + {1− ω(x; θ)} R̂Z,n(x). Note
that doptθ (x) = sign {Dθ(x)} and d̂θ,n(x) = sign
{
D̂θ,n(x)
}
. Let Pβ(x) = expit(x
⊺β),
ψi,A =
[
1
{
Ai = d
opt
θ0
(Xi)
}− Pβ0(Xi)]Xi, In(β) = En [Pβ(X) {1− Pβ(X)}XX⊺],
and I0 = E [Pβ0(X) {1− Pβ0(X)}XX⊺]. We use the following regularity condi-
tions.
Assumption 4. There exist independent and identically distributed influence vec-
tors ψ1,Y , ψ2,Y , . . . ∈ Rq1, and ψ1,Z , ψ2,Z , . . . ∈ Rq2, and vector basis functions φY (x)
and φZ(x) such that both∥∥∥∥∥√n{R̂Y,n(x)− RY (x)}− φY (x)⊺n−1/2
n∑
i=1
ψi,Y
∥∥∥∥∥
X
= oP (1)
and ∥∥∥∥∥√n{R̂Z,n(x)− RZ(x)}− φZ(x)⊺n−1/2
n∑
i=1
ψi,Z
∥∥∥∥∥
X
= oP (1).
Let ZY,n = n
−1/2
∑n
i=1 ψi,Y , ZZ,n = n
−1/2
∑n
i=1 ψi,Z , ZA,n = n
−1/2
∑n
i=1 ψi,A, and
q = q1 + q2. Furthermore, assume that ‖RY (x)‖X , ‖RZ(x)‖X ,
∥∥‖φY (x)‖∥∥X , and∥∥‖φZ(x)‖∥∥X are bounded by some M < ∞. Let Σ0 = E [{(ψ⊺1,Y , ψ⊺1,Z , ψ⊺1,A)⊺}⊗2]
be positive definite and finite, where u⊗2 = uu⊺.
Assumption 5. The following conditions hold.
1. The random variable Dθ0(X) has a continuous density function f in a neigh-
borhood of 0 with f0 = f(0) ∈ (0,∞);
2. The conditional distribution of X given that |Dθ0(X)| ≤ ǫ converges to a
non-degenerate distribution as ǫ ↓ 0;
3. There exist δ1, δ2 > 0 such that
lim
ǫ↓0
inf
t∈Sd
Pr
[|X⊺β0| ≥ δ1, | {RY (X)− RZ(X)} ω˙θ0(X)⊺t| ≥ δ1, |Dθ0(X)| ≤ ǫ] ≥ δ2,
where Sd is the d-dimensional unit sphere.
Assumption 6. Define, for ZY ∈ Rq1, ZZ ∈ Rq2, and U ∈ Rd,
(ZY , ZZ , U) 7→ k0(ZY , ZZ , U) = E
[
X {2Pβ0(X)− 1}·
∣∣ω(X; θ0)RY (X)φY (X)⊺ZY+
{1− ω(X; θ0)}RZ(X)φZ(X)⊺ZZ +R0(X)ω˙θ0(X)⊺U
∣∣∣∣∣Dθ0(X) = 0]. (4)
Assume that U 7→ β⊺0k0(ZY , ZZ , U) has a unique, finite minimum over Rd for all
(Z⊺Y , Z
⊺
Z)
⊺ ∈ Rq.
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Remark 1. Assumption 4 establishes a rate of convergence for the estimated Q-
functions and is automatically satisfied if the Q-functions are estimated using linear
or generalized linear models with or without interactions or higher order terms.
Assumption 5 is needed to ensure that there is positive probability of patients with
x values near the boundary between where each treatment is optimal. Assumption 6
is standard in M-estimation.
Let
(
θ̂n, β̂n
)
be the maximum pseudo-likelihood estimators given in Section 2.2.
The following theorem states the asymptotic distribution of
(
θ̂n, β̂n
)
.
Theorem 3.3 (Asymptotic distribution). Under the given regularity conditions
√
n
(
θ̂n − θ0
β̂n − β0
)
 
(
U
I−10 {ZA − k0(ZY , ZZ , U)}
)
≡
(
U
B
)
, (5)
where (Z⊺Y , Z
⊺
Z , Z
⊺
A)
⊺ ∼ N(0,Σ0), and U = argminu∈Rd β⊺0k0(ZY , ZZ , u).
Let
P
 
Z∗
denote convergence in probability over Z∗, as defined in Section 2.2.3
and Chapter 10 of Kosorok (2008). Theorem 3.4 below establishes the validity of
a parametric bootstrap procedure for approximating the sampling distribution of(
θ̂n, β̂n
)
.
Theorem 3.4 (Parametric bootstrap). Assume Σ̂n = Σ0 + oP (1) and hn =
v̂nn
−1/6, where v̂n
P−→ v0 ∈ (0,∞). Assume the regularity conditions given above
hold. Let Z∗ ∼ N(0, Ir×r), where Ir×r is an r × r identity matrix and r = p + q.
Let Z˜n = Σ̂
1/2
n Z∗ =
(
Z˜⊺Y , Z˜
⊺
Z , Z˜
⊺
A
)
⊺
. Let
T˜n(X, ZY , ZZ) = ω
(
X; θ̂n
)
R̂Y,n(X)φY (X)
⊺ZY+
{
1− ω
(
X; θ̂n
)}
R̂Z,n(X)φZ(X)
⊺ZZ
and define
k˜n(ZY , ZZ , U) = En
[
X
{
2Pβ̂n(X)− 1
}
·
∣∣∣T˜n(X, ZY , ZZ)
+
{
R̂Y,n(X)− R̂Z,n(X)
}
ω˙θ̂n(X)
⊺U
∣∣∣h−1n φ0 {D̂θ̂n,n(X)/hn}],
where φ0 is the standard normal density. Define U˜n = argminu∈Rd β̂
⊺
nk˜n
(
Z˜Y , Z˜Z , u
)
and B˜n = In
(
β̂n
)−1 {
Z˜A − k˜n
(
Z˜Y , Z˜Z , U˜n
)}
. Then,(
U˜n
B˜n
)
P
 
Z∗
(
U
B
)
, (6)
where (U⊺, B⊺)⊺ is as defined in Theorem 3.3.
10
If we fix a large number of bootstrap replications, B, then
(
U˜n,b, B˜n,b
)
, b =
1, . . . , B will provide an approximation to the sampling distribution of the maxi-
mum pseudo-likelihood estimators. In Sections 4 and 5, we demonstrate the use
of the bootstrap to test for heterogeneity of patient preferences.
4 Simulation Experiments
4.1 Fixed Utility Simulations
To examine the finite sample performance of the proposed methods, we begin
with the following simple generative model. Let X = (X1, . . . , X5)
⊺ be a vector
of independent normal random variables with mean 0 and standard deviation 0.5.
Let treatment be assigned according to Pr {A = doptω (x)|X = x} = ρ, i.e., the
probability that the clinician correctly identifies the optimal treatment is constant
across patients. Let ǫY and ǫZ be independent normal random variables with
mean 0 and standard deviation 0.5 and let Y = A (4X1 − 2X2 + 2) + ǫY and
Z = A (2X1 − 4X2 − 2) + ǫZ . We estimated QY and QZ using linear models,
implemented the proposed method for a variety of n, ω, and ρ values, and examined
ω̂n, ρ̂n, and d̂ω̂n,n, across 500 Monte Carlo replications.
Table 1 contains mean estimates of ω and ρ across replications along with the
associated standard deviation across replications, and estimated error rate defined
as the proportion of time the estimated optimal policy does not recommend the
true optimal treatment.
The pseudo-likelihood method performs well at estimating both ω and ρ, with
estimation improving with larger sample sizes as expected. Table 2 contains es-
timated values of the true optimal policy, a policy where the utility function is
estimated (the proposed method), policies estimated to maximize the two out-
comes individually (corresponding to fixing ω = 1 and ω = 0), and the standard of
care. The value of the standard of care is the mean composite outcome under the
generative model. For each policy, the value is estimated by generating a testing
sample of size 500 with treatment assigned according to the policy and averaging
utilities (calculated using the true ω) in the testing set. The standard deviation
across replications is included in parentheses. The column labeled “estimated ω”
refers to the proposed method. We see that the proposed method produces values
which increase with n and generally come close to the true optimal policy. In all
settings, the proposed method offers significant improvement over the standard
of care. The proposed method also offers improvement over policies to maximize
each individual outcome.
To further examine the performance of the proposed method, we allow the prob-
ability of optimal treatment to depend on patient covariates. Let Pr {A = doptω (X)} =
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n ω ρ ω̂n ρ̂n Error rate
100 0.25 0.60 0.29 (0.22) 0.62 (0.06) 0.10 (0.11)
0.23 (0.06) 0.80 (0.04) 0.03 (0.03)
0.75 0.60 0.63 (0.24) 0.62 (0.06) 0.13 (0.13)
0.73 (0.05) 0.80 (0.04) 0.03 (0.03)
200 0.25 0.60 0.28 (0.18) 0.61 (0.04) 0.08 (0.09)
0.24 (0.03) 0.80 (0.03) 0.02 (0.02)
0.75 0.60 0.68 (0.18) 0.61 (0.04) 0.08 (0.10)
0.74 (0.03) 0.80 (0.03) 0.02 (0.01)
300 0.25 0.60 0.25 (0.11) 0.61 (0.03) 0.05 (0.06)
0.24 (0.02) 0.80 (0.02) 0.01 (0.01)
0.75 0.60 0.72 (0.13) 0.61 (0.03) 0.06 (0.07)
0.74 (0.02) 0.80 (0.02) 0.01 (0.01)
500 0.25 0.60 0.23 (0.08) 0.60 (0.02) 0.04 (0.04)
0.24 (0.01) 0.80 (0.02) 0.01 (0.01)
0.75 0.60 0.73 (0.08) 0.60 (0.02) 0.04 (0.04)
0.75 (0.01) 0.80 (0.02) 0.01 (0.01)
Table 1: Estimation results for simulations where utility and probability of optimal
treatment are fixed.
n ω ρ Optimal Estimated ω Y only Z only Standard of care
100 0.25 0.60 1.90 (0.07) 1.75 (0.29) 0.39 (0.12) 1.77 (0.07) 0.39 (0.23)
1.90 (0.07) 1.88 (0.07) 0.39 (0.12) 1.77 (0.07) 1.14 (0.21)
0.75 0.60 1.89 (0.07) 1.69 (0.40) 1.76 (0.08) 0.39 (0.12) 0.40 (0.23)
1.89 (0.07) 1.89 (0.07) 1.76 (0.08) 0.39 (0.12) 1.15 (0.21)
200 0.25 0.60 1.90 (0.07) 1.80 (0.25) 0.39 (0.11) 1.77 (0.07) 0.38 (0.17)
1.90 (0.07) 1.89 (0.06) 0.39 (0.11) 1.77 (0.07) 1.15 (0.15)
0.75 0.60 1.90 (0.07) 1.79 (0.26) 1.76 (0.07) 0.38 (0.11) 0.38 (0.17)
1.90 (0.07) 1.89 (0.06) 1.76 (0.07) 0.38 (0.11) 1.16 (0.15)
300 0.25 0.60 1.90 (0.07) 1.86 (0.13) 0.37 (0.11) 1.76 (0.08) 0.38 (0.13)
1.90 (0.07) 1.89 (0.07) 0.37 (0.11) 1.76 (0.08) 1.14 (0.12)
0.75 0.60 1.90 (0.06) 1.84 (0.19) 1.76 (0.08) 0.39 (0.11) 0.39 (0.13)
1.90 (0.06) 1.90 (0.07) 1.76 (0.08) 0.39 (0.11) 1.15 (0.12)
500 0.25 0.60 1.90 (0.06) 1.88 (0.08) 0.38 (0.11) 1.77 (0.07) 0.37 (0.11)
1.90 (0.06) 1.90 (0.06) 0.38 (0.11) 1.77 (0.07) 1.13 (0.09)
0.75 0.60 1.90 (0.07) 1.88 (0.08) 1.76 (0.08) 0.39 (0.11) 0.37 (0.10)
1.90 (0.07) 1.90 (0.07) 1.76 (0.08) 0.39 (0.11) 1.13 (0.09)
Table 2: Value results for simulations where utility and probability of optimal
treatment are fixed.
expit(0.5 +X1). This corresponds to the case where β = (0.5, 1, 0, . . . , 0)
⊺, where
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the first element of β is an intercept. Let X, Y , and Z be generated as described
above. In this generative model, the probability that a patient is treated opti-
mally in standard care is larger for patients with positive values of X1 and smaller
for patients with negative values of X1. We applied the proposed method to 500
replications of this generative model for various n and ω. Table 3 contains mean
estimates of ω, root mean squared error (RMSE) of β̂n, and the error rate. Esti-
n ω ω̂n RMSE of β̂n Error rate
100 0.25 0.33 (0.24) 1.32 (0.49) 0.10 (0.14)
0.75 0.70 (0.21) 1.38 (0.45) 0.11 (0.10)
200 0.25 0.27 (0.14) 0.80 (0.30) 0.04 (0.08)
0.75 0.73 (0.14) 0.85 (0.28) 0.06 (0.07)
300 0.25 0.25 (0.08) 0.59 (0.21) 0.02 (0.05)
0.75 0.75 (0.10) 0.64 (0.21) 0.05 (0.05)
500 0.25 0.25 (0.03) 0.43 (0.14) 0.01 (0.01)
0.75 0.76 (0.07) 0.46 (0.15) 0.03 (0.03)
Table 3: Estimation results for simulations where utility is fixed and probability
of optimal treatment is variable.
mation of the observational policy (as defined by β) improves with larger sample
sizes. The probability that the estimated policy assigns the optimal treatment also
increases with the sample size. The true value of ω does not affect estimation of
ω or β.
Table 4 contains estimated values of the true optimal policy, a policy where the
utility function is estimated (the proposed method), policies estimated to maxi-
mize each outcome individually, and the standard of care. Values are estimated
from independent testing sets of size 500 as described above. The value under
the standard of care is the mean composite outcome under the generative model.
The proposed method (found in the column labeled “estimated ω”) produces val-
ues that are close to the true optimal policy in large samples and a significant
improvement over standard of care in small to moderate samples. We note that
value under the standard of care differs across ω. When ω is close to 1, the compos-
ite outcome places more weight on Y , for which the magnitude of the association
with X1 is larger. Because patients with larger values of X1 are more likely to be
treated optimally in this generative model, the standard of care produces larger
composite outcomes when ω is closer to 1. Likewise, the mean composite outcome
under policies to maximize each individual outcome varies with the true value of
ω.
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n ω Optimal Estimated ω Y only Z only Standard of care
100 0.25 1.90 (0.06) 1.72 (0.41) 0.40 (0.11) 1.76 (0.07) 0.33 (0.24)
0.75 1.90 (0.06) 1.76 (0.29) 1.76 (0.07) 0.38 (0.12) 0.58 (0.24)
200 0.25 1.90 (0.06) 1.84 (0.24) 0.38 (0.11) 1.75 (0.08) 0.32 (0.16)
0.75 1.90 (0.06) 1.84 (0.16) 1.76 (0.07) 0.38 (0.11) 0.57 (0.16)
300 0.25 1.89 (0.07) 1.88 (0.14) 0.38 (0.11) 1.77 (0.07) 0.32 (0.14)
0.75 1.90 (0.07) 1.87 (0.09) 1.76 (0.07) 0.39 (0.12) 0.56 (0.14)
500 0.25 1.90 (0.07) 1.90 (0.06) 0.38 (0.11) 1.77 (0.07) 0.33 (0.10)
0.75 1.90 (0.07) 1.89 (0.08) 1.76 (0.07) 0.39 (0.11) 0.57 (0.10)
Table 4: Value results for simulations where utility is fixed and probability of
optimal treatment is variable.
4.2 Patient-specific Utility Simulations
Next, we examine the case where the utility function is allowed to vary across pa-
tients. LetX, Y , and Z be generated as above. Again, assume that Pr
{
A = doptθ (X)
}
=
expit(0.5 + X1), i.e., β = (0.5, 1, 0, . . . , 0)
⊺. Consider the composite outcome
U = ω(X; θ)Y + {1− ω(X, θ)}Z, where ω(X; θ) = expit (1− 0.5X1), i.e., θ =
(1,−0.5, 0, . . . , 0)⊺, where the first element of θ is an intercept. We implemented
the proposed method for various n and examined estimation of θ and β across
500 replications. Each replication is based on a simulated Markov chain of length
10,000 as described in Section 2.2. Results are summarized in Table 5. Larger
n RMSE of θ̂n RMSE of β̂n Error rate
100 2.42 (0.99) 1.69 (0.62) 0.15 (0.08)
200 2.14 (0.91) 1.00 (0.33) 0.12 (0.06)
300 1.94 (0.83) 0.78 (0.25) 0.10 (0.05)
500 1.68 (0.74) 0.53 (0.17) 0.08 (0.04)
Table 5: Estimation results for simulations where both utility and probability of
optimal treatment are variable.
sample sizes produce marginal decreases in the RMSE of θ̂n. The estimated policy
assigns the true optimal treatment more than 80% of the time for all sample sizes
and the error rate decreases as the sample size increases. Table 6 contains esti-
mated values of the true optimal policy, the policy estimated using the proposed
method, policies estimated to maximize each outcome individually, and standard
of care. The proposed method produces policies that achieve significant improve-
ment over the standard of care across sample sizes.
Finally, we examine the performance of the parametric bootstrap as described
in Section 3. Let X be a bivariate vector of normal random variables with mean
14
n Optimal Estimated ω Y only Z only Standard of care
100 1.74 (0.06) 1.53 (0.19) 1.59 (0.07) 0.44 (0.11) 0.51 (0.21)
200 1.73 (0.06) 1.61 (0.13) 1.59 (0.07) 0.44 (0.10) 0.51 (0.15)
300 1.74 (0.06) 1.64 (0.12) 1.59 (0.07) 0.44 (0.10) 0.50 (0.13)
500 1.74 (0.06) 1.68 (0.09) 1.59 (0.07) 0.43 (0.10) 0.50 (0.09)
Table 6: Value results for simulations where both utility and probability of optimal
treatment are variable.
0, standard deviation 0.5, and correlation zero. Let Y and Z be generated as
above and let β = (2.5, 1, 0)⊺ where the first element of β is an intercept. Let θ(1)
be the vector θ with the first element removed. We are interested in testing the
null hypothesis H0 :
∥∥θ(1)∥∥ = 0, which corresponds to a test for heterogeneity of
patient preferences. The table below contains estimated power across 500 Monte
Carlo replications under the null hypothesis, where the true value is θ = (1, 0, 0)⊺,
and two alternative hypotheses: H1 : θ = (1, 4, 3)
⊺, and H2 : θ = (1, 6, 6)
⊺. All
tests were conducted at level α = 0.05 and based on 1000 bootstrap samples.
The proposed bootstrap procedure produces type I error rates near nominal levels
n Type 1 error Power against H1 Power against H2
100 0.014 0.190 0.272
200 0.020 0.409 0.572
300 0.048 0.497 0.649
500 0.066 0.528 0.682
Table 7: Power of bootstrap test for homogeneity of utility function
under the null and moderate power in large samples under alternative hypotheses.
5 Case Study: The STEP-BD Standard Care
Pathway
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-
BD) was a landmark study of the effects of antidepressants in patients with bipolar
disorder (Sachs et al., 2007). In addition to a randomized trial assessing outcomes
for patients given an antidepressant or placebo, the STEP-BD study also included a
large-scale observational study, the standard care pathway. We apply the proposed
method to data from the STEP-BD standard care pathway to estimate decision
rules for the use of antidepressants in patients with bipolar disorder.
Although bipolar disorder is characterized by alternating episodes of depression
and mania, recurrent depression is the leading cause of impairment among patients
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with bipolar disorder (Judd et al., 2002). However, the use of antidepressants has
not become standard care in bipolar disorder due to the risk of antidepressants in-
ducing manic episodes in certain patients (Ghaemi, 2008; Goldberg, 2008). Thus,
the clinical decision in the treatment of bipolar disorder is whether to prescribe an-
tidepressants to a specific patient in order to balance trade-offs between symptoms
of depression, symptoms of mania, and other side effects of treatment.
We use the SUM-D score for depression symptoms and the SUM-M score for
mania symptoms as outcomes. We consider a patient treated if they took any one
of ten antidepressants that appear in the STEP-BD standard care pathway (De-
seryl, Serzone, Citalopram, Escitalopram Oxalate, Prozac, Fluvoxamine, Parox-
etine, Zoloft, Venlafaxine, or Bupropion). Covariates used for this analysis were
age and substance abuse history (yes/no). Figure 1 contains box plots of SUM-D
scores on the log scale by substance abuse and treatment. Figure 2 contains box
plots of SUM-M scores on the log scale by substance abuse and treatment. For
both outcomes, lower scores are more desirable. Figure 1 indicates that those
0
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Figure 1: Box plots of log SUM-D by substance abuse and treatment.
without a history of substance abuse benefit from treatment with antidepressants.
However, among those with a history of substance abuse, patients treated with
antidepressants appear to have worse symptoms of depression. Figure 2 indicates
that treatment has no effect on symptoms of mania among those without a history
of substance abuse. However, among those with a history of substance abuse, it
appears that treatment may be inducing manic episodes. Thus, a sensible treat-
ment policy would be one that tends to prescribe antidepressants only to patients
without a history of substance abuse.
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Figure 2: Box plots of log SUM-M by substance abuse and treatment.
We analyzed these data using the proposed method for optimizing composite
outcomes. Results are summarized in Table 8 below. We estimated policies where
both utility and probability of optimal treatment are fixed (fixed-fixed), where
utility is fixed but probability of optimal treatment is assumed to vary between
patients (fixed-variable), and where both utility and probability of optimal treat-
ment are assumed to vary between patients (variable-variable). For both the fixed-
variable policy and the variable-variable policy, we report En
{
expit
(
X⊺β̂n
)}
in
place of ρ̂n and for the variable-variable policy, we report En
{
expit
(
X⊺θ̂n
)}
in
place of ω̂n. Thus, for parameters that are assumed to vary across patients, Table 8
contains the mean estimate in the sample. Mean outcomes and value functions are
averaged over five fold cross validation. For both SUM-D and SUM-M, lower scores
are preferred. Value is reported as the percent improvement over standard of care,
calculated using the estimated utility function. Large percent improvements in
value are preferred. All estimated policies produce more desirable SUM-D scores
Policy SUM-D SUM-M Value (% improvement) ω̂n ρ̂n
fixed-fixed 2.351 0.867 0.1% 0.115 0.403
fixed-variable 2.315 0.840 3.1% 0.115 0.405
variable-variable 2.297 0.838 7.1% 0.173 0.405
standard of care 2.480 0.868 0.0% · ·
Table 8: Results of analysis of STEP-BD data for SUM-D and SUM-M.
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and SUM-M scores compared to standard of care and improved value according
to the estimated utility. Allowing the probability of optimal treatment to vary be-
tween patients leads to further improvements in value, as does allowing the utility
function to vary between patients. All policies produce similar estimates for the
probability of optimal treatment averaged across patients.
The resulting decision rules can be written as the sign of a linear combination
of the covariates. As an example, the fixed-fixed policy assigns treatment with
antidepressants when sign {0.207− 0.003(age)− 0.620(substance abuse)} is equal
to 1. The negative coefficient for substance abuse means that a history of substance
abuse indicates that a patient should not be prescribed antidepressants. Prior
research has shown that patients with a history of substance abuse are more likely
to abuse antidepressants (Evans and Sullivan, 2014). This may contribute to the
poor outcomes experienced by STEP-BD patients with a history of substance
abuse who were treated with antidepressants. The coefficients in θ̂n in the variable-
variable policy were−0.007 for age and 7.582 for substance abuse, with an intercept
of −1.551. A test for preference heterogeneity based on 1000 bootstrap samples
generated according to Theorem 3.4 yielded a p-value < 0.001.
As a secondary analysis, we use the SUM-D score and a side effect score as out-
comes. Eight side effects were recorded in the STEP-BD standard care pathway
(tremors, dry mouth, sedation, constipation, diarrhea, headache, poor memory,
sexual dysfunction, and increased appetite). Patients rated the severity of each
side effect from 0 to 4 with larger values indicating more severe side effects. We
took the mean score across side effects as the second outcome. Patients in the stan-
dard care pathway were asked to report the percent of days over the past week that
they experienced mood elevation, irritability, and anxiety; these were included as
covariates along with age and history of substance abuse. Results are summarized
in Table 9, reported analogously to those in Table 8. Each estimated policy pro-
Policy SUM-D Side effect score Value (% improvement) ω̂n ρ̂n
fixed-fixed 2.341 0.153 5.6% 0.798 0.460
fixed-variable 2.393 0.150 6.9% 0.034 0.482
variable-variable 2.400 0.154 9.3% 0.239 0.460
standard of care 2.481 0.172 0.0% · ·
Table 9: Results of analysis of STEP-BD data for SUM-D and Side effect score.
duces improved SUM-D scores and improved side effect scores compared to the
standard of care. Each policy also produces improvement in value according to
the estimated utility function. Again, allowing the utility function to vary between
patients results in further improvements in value. Each policy produces similar
estimates of the probability that patients are treated optimally in standard care.
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The variable-variable policy places more weight on SUM-D scores on average com-
pared to the other policies. Estimated coefficients in θ̂n are −2.851 for age, −2.088
for substance abuse history, −1.159 for percent of days with mood elevation, 2.529
for percent days with irritability, and 0.048 for percent days with anxiety, with an
intercept of 0.673. The bootstrap procedure for testing the null hypothesis that
patient preferences are homogeneous based on 1000 bootstrap samples yielded a
p-value < 0.001.
6 Discussion
The estimation of individualized treatment rules has been well-studied in the sta-
tistical literature. Existing methods have typically defined the optimal treatment
rule as optimizing the mean of a fixed scalar outcome. However, clinical practice
often requires consideration of multiple outcomes. Thus, there is a disconnect be-
tween existing statistical methods and current clinical practice. It is reasonable
to assume that clinicians make treatment decisions for each patient with the goal
of maximizing that patient’s utility. Therefore, it is natural to use observational
data to estimate patient utilities from observed clinician decisions. This represents
a new paradigm for thinking about observational data, as traditional approaches
to analyzing observational data seek transformations under which the data can be
treated like a randomized study.
The proposed methodology offers many opportunities for future research. In
this paper, we have considered only the simplest case— that of one decision time,
two outcomes, and two possible treatments. Scenarios with more than two out-
comes are discussed in the Appendix, and the simulation results there demon-
strate that the proposed method performs well with three outcomes. Extensions
to more than two treatments or multiple time points represent potential areas for
future research. The proposed method requires positing a parametric model for
the utility function. Model misspecification is discussed in the Appendix, and the
simulation results there demonstrate that the proposed method performs reason-
ably well when important covariates are omitted from the model for the utility
function. Further study of model misspecification represents another area for fu-
ture research. Different computational strategies, such as a Bayesian approach,
could be developed to handle the non-smooth pseudo-likelihood and potentially
improve estimation of patient-specific utility functions. While we have proposed
our utility function estimator inside the framework of one-stage Q-learning, the
pseudo-likelihood utility function estimator could be used alongside other existing
one-stage optimal treatment policy estimators, such as an outcome weighted learn-
ing estimator (Zhao et al., 2012). There is a great future for the development of
methods for optimizing composite outcomes in precision medicine and application
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of these methods in clinical studies.
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Appendix
Proofs
Proof of Theorem 3.1. The log of the pseudo-likelihood is given by
ℓ̂n(θ, β) = En
[
X⊺β1
{
A = d̂θ,n(X)
}
− log {1 + exp (X⊺β)}
]
.
Let m̂(·, ·; θ, β) : X×A → R be defined by m̂(X, A; θ, β) = X⊺β1
{
A = d̂θ,n(X)
}
−
log {1 + exp (X⊺β)} and consider the class of functions {m̂(·, ·; θ, β) : θ ∈ Rp, β ∈ B}.
The class {log {1 + exp(X⊺β)} : β ∈ B} is contained in a VC class by Lemma 9.9
(viii) and (v) of Kosorok (2008). By Theorem 9.3 of Kosorok (2008), this is also a
Glivenko–Cantelli (GC) class.
Let u(X, A; θ) = ω(X; θ)
{
Q̂Y,n(X, A)− Q̂Z,n(X, A)
}
− Q̂Z,n(X, A), which lies
in a VC class indexed by θ ∈ Rp by Lemma 9.6 and Lemma 9.9 (viii), (vi), and
(v) of Kosorok (2008). We have that
1
{
A = d̂θ,n(X)
}
= 1(A = 1)1 {u(X, 1; θ)− u(X,−1, θ) ≥ 0}
+ 1(A = −1)1 {u(X, 1; θ)− u(X,−1, θ) < 0} ,
and it follows that 1
{
A = d̂θ,n(X)
}
is contained in a GC class indexed by θ ∈ Rp.
From Corollary 9.27 (ii) of Kosorok (2008) it follows thatX⊺β1
{
A = d̂θ,n(X)
}
lies
in a GC class indexed by (θ, β) ∈ Rp ×B as long as X⊺β is uniformly bounded by
a function with finite mean, which holds as long as B is compact and ‖EX‖ <∞.
It follows that
sup
(θ,β)∈Rp×B
∣∣∣(En − E) [X⊺β1{A = d̂θ,n(X)}− log {1 + exp(X⊺β)}]∣∣∣ P−→ 0.
Next, define
M̂(θ, β) = E {m̂(X, A; θ, β)} = E
(
X⊺βE
[
1
{
A = d̂θ,n(X)
}
|X
])
−E log {1 + exp(X⊺β)}
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and note that M̂(θ, β) is continuous in β. The inside expectation of the first piece
is
E
[
1
{
A = d̂θ,n(X)
}
|X
]
= expit(X⊺β0)1
{
d̂θ,n(X) = d
opt
θ0
(X)
}
+ {1− expit(X⊺β0)} 1
{
d̂θ,n(X) 6= doptθ0 (X)
}
,
using the fact that Pr
{
A = doptθ0 (X)
}
= expit(X⊺β0). Define a(X) = QY (X, 1)−
QY (X,−1)−QZ(X, 1)+QZ(X,−1) and b(X) = QZ(X, 1)−QZ(X,−1). Similarly,
define â(X) = Q̂Y,n(X, 1)− Q̂Y,n(X,−1)− Q̂Z,n(X, 1) + Q̂Z,n(X,−1) and b̂(X) =
Q̂Z,n(X, 1)− Q̂Z,n(X,−1). Then,
1
{
d̂θ,n(X) = d
opt
θ0
(X)
}
= 1
[{
ω(X; θ)â(X) + b̂(X)
}
{ω(X; θ)a(X) + b(X)} ≥ 0
]
= 1
[
ω(X; θ) {ω(X; θ)a(X)â(X) + â(X)b(X)}
+ω(X; θ)a(X)̂b(X) + b̂(X)b(X) ≥ 0
]
,
and thus E
[
1
{
A = d̂θ,n(X)
}
|X
]
is continuous in θ.
Let m(X, A; θ, β) = X⊺β1
{
A = doptθ (X)
} − log {1 + exp (X⊺β)}. Because the
model is identifiable and Ln(θ, β) is a parametric log-likelihood, Em(X, A; θ, β) has
unique maximizers at θ0 and β0. Let θ˜ and β˜ be the maximizers of Em̂(X, A; θ, β).
Because E
{
d̂θ,n(X)|X = x
}
= doptθ (x) for any x ∈ X and θ ∈ Rp, E
[
1
{
A = d̂θ,n(X)
}
|X
]
=
E
[
1
{
A = doptθ (X)
} |X], which implies that Em(X, A; θ, β) = Em̂(X, A; θ, β). Thus,
θ˜ = θ0 and β˜ = β0. The claim now follows from Lemma 14.3 and Theorem 2.12 of
Kosorok (2008).
Proof of Theorem 3.2. Define Qθ0(x, a) and Qθ̂n(x, a) as defined in Section 2. Let
u(Y, Z;A,X, θ) = ω(X; θ)QY (X, A) + {1− ω(X; θ)}QZ(X, A). Under the given
assumptions, for some constant 0 < c <∞,∣∣∣V (d̂θ̂n,n)− V (doptθ0 )∣∣∣
≤ c
∣∣∣∣E{u(Y, Z;A,X, θ0)− Q̂θ̂n,n(X, A)}2 − E {u(Y, Z;A,X, θ0)−Qθ0(X, A)}2∣∣∣∣1/2
(7)
by equation (3.1) of Qian and Murphy (2011) (see also Murphy, 2005). The right
hand side of (7) converges in probability to 0 by the consistency of θ̂n, consistency
of Q̂Y,n and Q̂Z,n, and the continuous mapping theorem. The result follows.
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Proof of Theorem 3.3. By definition of
(
θ̂n, β̂n
)
,
0 ≤ ℓ̂n
(
θ̂n, β̂n
)
− ℓ̂n (θ0, β0)
=
n∑
i=1
[
X
⊺
i β̂n1
{
Ai = d̂θ̂n,n(Xi)
}
−X⊺i β01
{
Ai = d̂θ0,n(Xi)
}
−
(
β̂n − β0
)
⊺
XiPβ0(Xi)
]
− 1
2
√
n
(
β̂n − β0
)
⊺
In(β∗)
√
n
(
β̂n − β0
)
=
√
n
(
β̂n − β0
)
⊺
n−1/2
n∑
i=1
Xi
[
1
{
Ai = d̂θ̂n,n(Xi)
}
− Pβ0(Xi)
]
−1
2
√
n
(
β̂n − β0
)
⊺
In(β∗)
√
n
(
β̂n − β0
)
+
n∑
i=1
X
⊺
i β0
[
1
{
Ai = d̂θ̂n,n(Xi)
}
− 1
{
Ai = d̂θ0,n(Xi)
}]
,
where β∗ is a point between β̂n and β0. Using the definition of a maximizer
and letting ûn(θ) = n
−1/2
∑n
i=1Xi
[
1
{
Ai = d̂θ,n(Xi)
}
− Pβ0(Xi)
]
, we have that
√
n
(
β̂n − β0
)
= In(β∗)
−1ûn
(
θ̂n
)
, since In(β∗)
P−→ I0 and I0 is positive definite.
Next, note that
ûn
(
θ̂n
)
= n−1/2
n∑
i=1
Xi
[
1
{
Ai = d̂θ̂n,n(Xi)
}
− 1{Ai = doptθ0 (Xi)}]+ ZA,n
= Gn
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])+ ZA,n
+
√
nE
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])
= ZA,n +
√
nE
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}]) {1 + oP (1)} ,
whereGnf = n
1/2(En−E)f(X). We also have 1
{
A = d̂θ̂n,n(X)
}
−1{A = doptθ0 (X)} =
− [2 · 1{A = doptθ0 (X)}− 1] 1{d̂θ̂n,n(X) 6= doptθ0 (X)}, which implies that
√
nE
(
X
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])
= −√nE
[
X {2Pβ0(X)− 1} 1
{
d̂θ̂n,n(X) 6= d
opt
θ0
(X)
}]
= −√nE
{
X {2Pβ0(X)− 1}
(
1
[
0 ≤ Dθ0(X) < −
{
D̂θ̂n,n(X)−Dθ0(X)
}]
+1
[
−
{
D̂θ̂n,n(X)−Dθ0(X)
}
≤ Dθ0(X) < 0
] )}
= −E
[
X {2Pβ0(X)− 1} ·
∣∣∣√n{D̂θ̂n,n(X)−Dθ0(X)}∣∣∣ ∣∣∣Dθ0(X) = 0] f0 + oP (1)
22
by Assumption 5 and the fact that
∥∥∥D̂θ̂n,n(x)−Dθ0(x)∥∥∥X = oP (1). Note that
√
n
{
D̂θ̂n,n(X)−Dθ0(X)
}
=
√
n
[
ω
(
X; θ̂n
){
R̂Y,n(X)− RY (X)
}
+
{
1− ω
(
X; θ̂n
)}{
R̂Z,n(X)−RZ(X)
}]
+
√
n
{
ω
(
X; θ̂n
)
− ω (X; θ0)
}
{RY (X)− RZ(X)}
= ω (X; θ0)φY (X)
⊺ZY,n + {1− ω (X; θ0)}φZ(X)⊺ZZ,n
+ω˙θ0(X) {RY (X)− RZ(X)}
√
n
(
θ̂n − θ0
)
{1 + oP (1)}
= OP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥) ,
thus,
∥∥∥ûn (θ̂n)∥∥∥ = OP (1 +√n ∥∥∥θ̂n − θ0∥∥∥). Letting vn (θ̂n, β∗) = n−1/2ûn (θ̂n)⊺ In(β∗)ûn (θ̂n),
0 ≤ n−1/2
{
ℓ̂n
(
θ̂n, β̂n
)
− ℓ̂n (θ0, β0)
}
= n−1/2
n∑
i=1
X
⊺
iβ0
[
1
{
Ai = d̂θ̂n,n(X)
}
− 1
{
Ai = d̂θ0,n(X)
}]
+ vn
(
θ̂n, β∗
)
/2
= n1/2E
(
X⊺β0
[
1
{
A = d̂θ̂n,n(X)
}
− 1
{
A = d̂θ0,n(X)
}])
+ oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥)
= n1/2E
(
X⊺β0
[
1
{
A = d̂θ̂n,n(X)
}
− 1{A = doptθ0 (X)}])
−n1/2E
(
X⊺β0
[
1
{
A = d̂θ0,n(X)
}
− 1{A = doptθ0 (X)}])+ oP (1 +√n ∥∥∥θ̂n − θ0∥∥∥)
= E
[
X⊺β0 {2Pβ0(X)− 1} ·
∣∣∣√n{D̂θ̂n,n(X)−Dθ0(X)}∣∣∣ ∣∣∣Dθ0(X) = 0] f0rn
+OP (1) + oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥)
≤ −E
[
X⊺β0 {2Pβ0(X)− 1} ·
∣∣∣{RY (X)− RZ(X)} ω˙θ0(X)⊺ (θ̂n − θ0)∣∣∣ ∣∣∣Dθ0(X) = 0] f0rn
+OP (1) + oP
(
1 +
√
n
∥∥∥θ̂n − θ0∥∥∥)
≤ −δ2δ21
(
exp(δ1)− 1
exp(δ1) + 1
)√
n
∥∥∥θ̂n − θ0∥∥∥ {1 + oP (1)}+OP (1) + oP (1 +√n ∥∥∥θ̂n − θ0∥∥∥) ,
where rn = 1 + oP (1). This implies that
√
n
∥∥∥θ̂n − θ0∥∥∥ = OP (1). Let
Mn
(
θ̂n
)
= n−1/2
n∑
i=1
X
⊺
i β0
[
1
{
Ai = d̂θ̂n,n(X)
}
− 1
{
Ai = d̂θ0,n(X)
}]
+vn
(
θ̂n, β∗
)
/2,
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let M(u) = β⊺0k0(ZY , ZZ , u), and let U = argminu∈RdM(u). We will show that
Mn(θ0 + u/
√
n)  M(u) in ℓ∞(K) for any compact subset K of Rd. Then, it
will follow from the argmax Theorem (See chapter 14 of Kosorok, 2008) that
U˜n  U , where U˜n = argminu∈RdMn(θ0+u/
√
n). Let hn(u) = θ0+u/
√
n. Similar
arguments along with Assumptions 6 and 5, yield that, for any compact K ⊂ Rd,
argmin
u∈K
Mn {hn(u)} = argmin
u∈K
n1/2E
(
X⊺β0
[
1
{
A = d̂hn(u),n(X)
}
− 1{A = doptθ0 (X)}])
= argmin
u∈K
n1/2E
{
X⊺β0 {2Pβ0(X)− 1}
(
1
[
−
{
D̂hn(u),n(X)−Dθ0(X)
}
≤ Dθ0(X) < 0
]
+ 1
[
0 ≤ Dθ0(X) < −
{
D̂hn(u),n(X)−Dθ0(X)
}])}
= argmin
u∈K
E
[
X⊺β0 {2Pβ0(X)− 1}
∣∣∣√n{D̂hn(u),n(X)−Dθ0(X)}∣∣∣∣∣∣Dθ0(X) = 0]f0 + oP (1),
However,
√
n
{
D̂hn(u),n(X)−Dθ0(X)
}
 ω (X; θ0)φY (X)
⊺ZY +{1− ω (X; θ0)}φZ(X)⊺ZZ
+R0(X)ω˙θ0(X)
⊺u
uniformly over X when X has its conditional distribution given Dθ0(X) = 0. This
implies that Mn(θ + u/
√
n) M(u) in ℓ∞(K) as desired and thus U˜n  U . It is
straightforward to verify the remaining conclusions of the theorem using previous
arguments.
Proof of Theorem 3.4. Using the assumptions, the fact that both
√
n
(
θ̂n − θ0
)
=
OP (1) and
√
n
(
β̂n − β0
)
= OP (1), and standard arguments, we obtain that, for
any compactK1 ⊂ Rq, sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1
∥∥∥T˜n {x, Z˜Y (ZY ), Z˜Z(ZZ)}− T0(x, ZY , ZZ)∥∥∥
X
=
oP (1), where Z˜Y (ZY ) = Σ̂
1/2
n Σ
−1/2
0 (Z
⊺
Y , 0
⊺, 0⊺)⊺, Z˜Z(ZZ) = Σ̂
1/2
n Σ
−1/2
0 (0
⊺, Z⊺Z , 0
⊺)⊺,
and also T0(x, ZY , ZZ) = ω(x; θ0)φY (x)
⊺ZY + {1− ω(x; θ0)}φZ(x)⊺ZZ . Further-
more, ∥∥∥{R̂Y,n(x)− R̂Z,n(x)} ω˙θ̂n(x)⊺u− {RY (x)−RZ(x)} ω˙θ0(x)⊺u∥∥∥X
≤
∥∥∥∥ ∥∥∥{R̂Y,n(x)− R̂Z,n(x)} ω˙θ̂n(x)− {RY (x)− RZ(x)} ω˙θ0(x)∥∥∥ ∥∥∥∥
X
· ‖u‖
= OP
(
n−1/2
) ‖u‖,
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∥∥∥D̂θ̂n,n(x)−Dθ0(x)∥∥∥X = OP (n−1/2), and ∥∥∥Pβ̂n(x)− Pβ0(x)∥∥∥X = OP (n−1/2). Thus,
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
En
[
‖X‖ ·
∣∣∣{2Pβ̂n(X)− 1} T˜n {X, Z˜Y (ZY ), Z˜Z(ZZ)}∣∣∣ 1hnφ0
{
D̂θ̂n,n(X)
hn
}]
≤ OP (1)En
[
1
hn
φ0
{
D̂θ̂n,n(X)
hn
}]
. (8)
However,
En
(
1
hn
[
φ0
{
D̂θ̂n,n(X)
hn
}
− φ0
{
Dθ0(X)
hn
}])
= En
[
1
h3n
∫ 1
0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
}
φ0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
hn
}
ds
·
{
D̂θ̂n,n(X)−Dθ0(X)
}]
= OP
(
1
h3nn
1/2
)
En
[∫ 1
0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
}
φ0
{
(1− s)Dθ0(X) + sD̂θ̂n,n(X)
hn
}
ds
]
= OP
(
1
h3nn
1/2
)
OP (hn) = OP
(
1
h3nn
1/2
)
= oP (1),
since |uφ0(u)| ≤ (2π)−1/2e−1 < ∞. Now, since E [h−1n φ0 {Dθ0(X)/hn}] P−→ f0, we
have that (8) is equal to OP (1). Thus, if ‖un‖ → ∞,
β̂⊺nk˜n
(
Z˜Y , Z˜Z , un
)
≥ En
[
β̂⊺nX
{
2Pβ̂n(X)− 1
}
·
∣∣∣{R̂Y,n(X)− R̂Z,n(X)} ω˙θ̂n(X)⊺un∣∣∣
· 1
hn
φ0
{
D̂θ̂n,n(X)
hn
}]
− OP (1), (9)
where the OP (1) is uniform over K1. Thus, up to the OP (1) added on the right-
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hand side,
(9) ≥ ‖un‖ inf
t∈Sd
En
[
β̂⊺nX
{
2Pβ̂n(X)− 1
} ∣∣∣{R̂Y,n(X)− R̂Z,n(X)} ω˙θ̂n(X)⊺t∣∣∣ 1hnφ0
{
D̂θ̂n,n(X)
hn
}]
≥ ‖un‖
(
oP (1) + inf
t∈Sd
E
[
β⊺0X {2Pβ0(X)− 1} |{RY (X)− RZ(X)} ω˙θ0(X)⊺t|
1
hn
φ0
{
Dθ0(X)
hn
}])
= ‖un‖
(
oP (1) + inf
t∈Sd
E
[
β⊺0X {2Pβ0(X)− 1} |{RY (X)− RZ(X)} ω˙θ0(X)⊺t|
∣∣∣Dθ0(X) = 0] f0)
≥ ‖un‖
[
oP (1) + δ2δ
2
1
{
exp(δ1)− 1
exp(δ1) + 1
}]
,
with the expectation overX. Let Ûn (ZY , ZZ) = argminu∈Rd β̂
⊺
nk˜n
{
Z˜Y (ZY ) , Z˜Z (ZZ) , u
}
,
where, if the arg min set has more than one element, one can be chosen randomly
or algorithmically. Since the OP (1) above is uniform over K1, we conclude that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
∥∥∥Ûn (ZY , ZZ)∥∥∥ = OP (1). (10)
Now, letK2 be any compact subset of R
d. Previous and standard arguments give us
that sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1 supu∈K2
∥∥∥k˜n {Z˜Y (ZY ) , Z˜Z (ZZ) , u}− k0 (ZY , ZZ , u)∥∥∥ = oP (1).
Thus, we also have that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
sup
u∈K2
∥∥∥β̂⊺nk˜n {Z˜Y (ZY ) , Z˜Z (ZZ) , u}− β⊺0k0 (ZY , ZZ , u)∥∥∥ = oP (1). (11)
Define U0(ZY , ZZ) = argmaxu∈Rdβ
⊺
0k0(ZY , ZZ , u). Previous arguments yield that
sup
(Z⊺
Y
,Z⊺
Z
)⊺∈K1
‖U0(ZY , ZZ)‖ = O(1). (12)
By Assumption 6, the arg min for each (Z⊺Y , Z
⊺
Z)
⊺ ∈ K1 is unique. Fix ǫ > 0.
By (10), there exists anm2 <∞ such that Pr
(
sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1
∥∥∥Ûn (ZY , ZZ)∥∥∥ < m2) ≥
1− ǫ for all n large enough. By (12), we can enlarge m2 such that
sup(Z⊺
Y
,Z⊺
Z
)⊺∈K1 ‖U0(ZY , ZZ)‖ < m2 <∞.
We can also find an m1 < ∞ such that K1 ⊂ Kqm1 as defined in Corollary 7.2.
It is straightforward to show that (1) and (3) in Corollary 7.2 are satisfied by
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f(Z, u) = β⊺0k0(ZY , ZZ , u), where Z = (Z
⊺
Y , Z
⊺
Z)
⊺
. Let fn(Z, u) = β̂
⊺
nk˜n(ZY , ZZ , u).
Standard arguments and the given assumptions yield that there exists a w1 < ∞
such that supZ∈Kqm1 supu∈Kdm2
|fn(Z, u)| < w1 almost surely and
sup
Z1,Z2∈K
q
m1:‖Z1−Z2‖<δ
‖fn(Z1, u)− fn(Z2, u)‖Kdm2 < w1δ
for all δ > 0 and all n ≥ 1 almost surely. Every subsequence in (11) has a further
subsequence n′′ on which the convergence in probability to zero can be replaced
with almost sure convergence. Thus, (2) and (4) of Corollary 7.2 apply, using the
fact that minimizing is equivalent to maximizing after a change in sign. Setting
Û∗n(ZY , ZZ) = argminu∈Kdm2
β̂⊺nk˜n
{
Z˜Y (ZY ) , Z˜Z (ZZ) , u
}
, Corollary 7.2 yields that
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Û∗n′′(ZY , ZZ)− U0(ZY , ZZ)∥∥∥→ 0
almost surely. Since this is true for every subsequence, we have that
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Û∗n(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ P−→ 0
as n→∞. Note that, on K2, Û∗n(ZY , ZZ) = Ûn(ZY , ZZ) for all (Z⊺Y , Z⊺Z)⊺ ∈ Kqm1 .
Hence,
lim sup
n→∞
Pr
 sup(Z⊺Y ,Z⊺Z)⊺∈Kqm1
∥∥∥Ûn(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ > ǫ

≤ lim sup
n→∞
[
Pr
Ûn(ZY , ZZ) ∈ K2, sup(Z⊺Y ,Z⊺Z)⊺∈Kqm1
∥∥∥Û∗n(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ ≥ ǫ

+Pr
{
Ûn(ZY , ZZ) ∈ Kc2
}]
≤ ǫ.
Since ǫ was arbitrary, we obtain that
sup
(Z⊺Y ,Z
⊺
Z)
⊺
∈Kqm1
∥∥∥Ûn(ZY , ZZ)− U0(ZY , ZZ)∥∥∥ = oP (1).
Let BL(B) be the space of all Lipschitz continuous functions mapping B → R
which are bounded by 1 and which have Lipschitz constant 1. Let EZ be ex-
pectation with respect to Z∗0 = (Z
∗
Y
⊺, Z∗Z
⊺, Z∗A
⊺)⊺ ∼ N(0,Σ0). Let B0 (Z∗0) =
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I−10
[
Z∗A − k0
{
Z∗Y , Z
∗
Z , U˜n (Z
∗
0)
}]
and let f ∈ BL
(
Rd+p
)
. Then,∣∣∣EZ [f {U˜n(Z∗0 ), B˜n(Z∗0)}− f {U0(Z∗0), B0(Z∗0 )}]∣∣∣
≤
∣∣∣EZ [f {U˜n(Z∗0), B˜n(Z∗0)}− f {U0(Z∗0), B˜n(Z∗0)}]∣∣∣
+
∣∣∣EZ [f {U0(Z∗0 ), B˜n(Z∗0 )}− f {U0(Z∗0), B0(Z∗0)}]∣∣∣
=
∣∣∣EZ [f1 {U˜n(Z∗0)}− f1 {U0(Z∗0)}]∣∣∣+ ∣∣∣EZ [f2 {B˜n(Z∗0)}− f2 {B0(Z∗0)}]∣∣∣
for some other f1 ∈ BL
(
R
d
)
and f2 ∈ BL (Rp). Hence,
sup
f∈BL(Rd+p)
∣∣∣EZf {U˜n(Z∗0), B˜n(Z∗0)}− EZf {U0(Z∗0), B0(Z∗0 )}∣∣∣
≤ sup
f∈BL(Rd)
∣∣∣EZf {U˜n(Z∗0 )}− EZf {U0(Z∗0)}∣∣∣
+ sup
f∈BL(Rp)
∣∣∣EZf {B˜n(Z∗0 )}− EZf {B0(Z∗0)}∣∣∣
= An +Bn,
where we define both An = supf∈BL(Rd)
∣∣∣EZf {U˜n(Z∗0)}− EZf {U0(Z∗0)}∣∣∣ and
Bn = supf∈BL(Rp)
∣∣∣EZf {B˜n(Z∗0 )}− EZf {B0(Z∗0 )}∣∣∣. Fix some compact K1 ⊂ Rq
such that Pr {(Z∗Y ⊺, Z∗Z⊺)⊺ ∈ K1} ≥ 1− ǫ. Then,
sup
f∈BL(Rd)
∣∣∣EZ [f {U˜n(Z∗0)}− EZf {U0(Z∗0 )}]∣∣∣
≤ sup
f∈BL(Rd)
∣∣∣EZ1 (Z∗0 ∈ K1) f {U˜n(Z∗0)}− EZ1 (Z∗0 ∈ K1) f {U0 (Z∗0)}∣∣∣
+2EZ1 (Z
∗
0 ∈ K1)
= oP (1) + 2ǫ,
which implies that An = oP (1) since ǫ was arbitrary. For K2 ⊂ Rq+p such that
Pr (Z∗0 ∈ K2) ≥ 1− ǫ, previous arguments yield that
supZ∗
0
∈K2
∥∥∥B˜n(Z∗0 )−B0(Z∗0)∥∥∥ = oP (1).
As before, we can argue that Bn = oP (1) + 2ǫ, which implies that Bn = oP (1)
since ǫ was arbitrary. The result follows.
Theorem 7.1. Let H be a compact set in a metric space with metric d and let F be
a compact subset of C[H ] with respect to the uniform norm, ‖·‖H. For each f ∈ F ,
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let u(f) = argmaxh∈Hf(h), where, when the arg max is not unique, we select one
element of the arg max set either randomly or algorithmically. Suppose also that
there exists a closed F1 ⊂ F for which each f ∈ F1 has a unique maximum. Then,
lim
δ↓0
sup
f∈F1
sup
g∈F :‖f−g‖H<δ
d {u(f), u(g)} = 0.
Proof of Theorem 7.1. Fix ǫ > 0. For each f ∈ F1, there exists δf > 0 such that
sup
h∈H∩Bǫ{u(f)}
c
f(h) < f {u(f)} − 2δf ,
where Bǫ(u) is the open d-ball of radius ǫ around u. This follows since the compact-
ness of F ensures that all f ∈ F are continuous. Let g ∈ F be such that ‖f−g‖H <
δf . Then, f {u(g)} > g {u(g)}−δf ≥ g {u(f)}−δf > f {u(f)}−2δf , which implies
that d {u(g), u(f)} < ǫ. We have that ∪f∈F1 {g ∈ F : ‖g − f‖H < δf} is an open
cover of F1. Since F1 is compact, there exists a set F ǫ1 such that F ǫ1 is finite and
∪f∈Fǫ
1
{g ∈ F : ‖g − f‖H < δf} still covers F1. Let {fn} ∈ F1 and {gn} ∈ F be
sequences. By compactness, every subsequence has a further subsequence n′′ such
that fn′′ → f0 ∈ F1 and gn′′ → g0 ∈ F so that both f0 and g0 are in a set of the form
{g ∈ F : ‖g − f‖H < δf} for some f ∈ F ǫ1. This implies that d {u(g0), u(f0)} < ǫ.
Since the subsequence was arbitrary, we have that lim supn→∞d {u(gn), u(fn)} ≤ ǫ.
Since ǫ was arbitrary, we now have that lim supn→∞d {u(gn), u(fn)} = 0, which
proves the result.
Corollary 7.2. For m1 < ∞, let Kqm1 = {z ∈ Rq : ‖z‖ ≤ m1}. Let (z, u) 7→
f(z, u) and (z, u) 7→ fn(z, u) be a fixed function and a sequence of functions,
respectively, from Kqm1 ×Rd to R. Suppose there exists m2 <∞ such that for each
z ∈ Kqm1 , u(z) = argmaxu∈Rdf(z, u) < m2 and is uniquely defined. Suppose also
that un(z) = argmaxu∈Rdfn(z, u) < m2 for all n large enough, where we allow the
arg max to be non-unique, but we randomly or algorithmically select one element
from the arg max set. Define Kdm2 similarly to K
q
m1
and assume that
1. supz∈Kqm1 supu∈Kdm2
|f(z, u)| <∞
2. lim supn→∞ supz∈Kqm1
supu∈Kdm2
|fn(z, u)| <∞
3. limδ↓0 supz1,z2∈Kqm1 :‖z1−z2‖<δ ‖f(z1, u)− f(z2, u)‖Kdm2 = 0
4. limδ↓0 supz1,z2∈Kqm1 :‖z1−z2‖<δ ‖fn(z1, u)− fn(z2, u)‖Kdm2 = 0
for all n large enough. Then, provided supz∈Kqm1 ‖fn(z, ·)− f(z, ·)‖Kdm2 → 0,
sup
z∈Kqm1
‖un(z)− u(z)‖ → 0
as n→∞.
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Corollary 7.2. By the Arzela`–Ascoli Theorem, there exists a compact K ⊂ C[H ]
for H = Kdm2 , such that both f(z, ·) ∈ K and fn(z, ·) ∈ K for all n large enough.
If we let F1 =
{
f(z, ·) : z ∈ Kqm1
}
, we can directly apply Theorem 7.1 to obtain
that
lim
δ↓0
sup
z∈Kqm1
sup
g∈K:‖g−f(z,·)‖H<δ
‖u(g)− u {f(z, ·)}‖H = 0.
Because supz∈Kqm1
‖fn(z, ·)− f(z, ·)‖Kdm2 < δ for all n large enough, the result
follows.
Three or More Outcomes
Assume the available data consist of (Xi, Ai, Y1,i, . . . , YK,i), i = 1, . . . , n, which
comprise n independent and identically distributed copies of (X, A, Y1, . . . , YK),
where X and A are as defined previously, and Y1, . . . , YK are outcomes, with each
outcome coded so that higher values are better. Assume that exists and unknown
utility function U = u(Y1, . . . , YK), where u : R
K → R, such that u(y1, . . . , yK)
quantifies the “goodness” of the outcome vector (y1, . . . , yK). As before, let U
∗(d)
be the potential utility under a treatment regime d. Let doptU be the optimal regime
for the utility defined by u, i.e., EU∗
(
doptU
) ≥ EU∗(d) for any regime d. The goal is
to estimate the utility function and the associated optimal regime in the presence
of more than two outcomes.
To begin, we assume that the utility function is constant across patients and
takes the form u(y1, . . . , yK ;ω) =
∑K−1
k=1 ωkyk +
(
1−∑K−1k=1 ωk) yK , where ω =
(ω1, . . . , ωK−1) is a vector of parameters with
∑K−1
k=1 ωk ≤ 1 and ωk ≥ 0 for
k = 1, . . . , K − 1. Thus, we assume that the utility function is a convex com-
bination of the set of outcomes. Let doptω be the optimal regime for the utility
defined by ω. Assume that there exists a true utility function defined by some
ω0 = (ω1,0, . . . , ωK−1,0) such that observed decisions were made with the intent
to maximize U = u(y1, . . . , yK ;ω0). Further assume that treatment decisions in
the observed data follow Pr
{
A = doptω0 (x)|X = x
}
= expit (x⊺β) , where β is an
unknown parameter.
Define QYk(x, a) = E (Yk|X = x, A = a), for k = 1, . . . , K. Define Qω(x, a) =
E {u (Y1, . . . , YK;ω) |X = x, A = a} and note that Qω(x, a) =
∑K−1
k=1 ωkQYk(x, a)+(
1−∑K−1k=1 ωk)QYK (x, a). The Q-functions for each outcome can be estimated
from the observed data using regression models. Let Q̂Yk,n(x, a) denote an estima-
tor forQYk(x, a). Then, an estimator forQω(x, a) is Q̂ω,n(x, a) =
∑K−1
k=1 ωkQ̂Yk,n(x, a)+(
1−∑K−1k=1 ωk) Q̂YK ,n(x, a). For any fixed ω, we can compute an estimator for doptω
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as d̂ω,n(x) = argmaxa∈A Q̂ω,n(x, a). The pseudo-likelihood is
L̂n(ω, β) ∝
n∏
i=1
exp
[
X
⊺
i β1
{
Ai = d̂ω,n(Xi)
}]
1 + exp (X⊺i β)
, (13)
for a vector β and a vector ω = (ω1, . . . , ωK−1). For K = 2, this reduces to the
formulation in Section 2. Estimators for β and ω1, . . . , ωK−1 can be obtained by
maximizing the pseudo-likelihood in (13). Letting ω̂n = (ω̂1,n, . . . , ω̂K−1,n denote
the maximum pseudo-likelihood estimator for ω, an estimator for the optimal
regime is d̂ω̂n,n(x) = argmaxa∈AQ̂ω̂n,n(x, a).
When the number of outcomes is large, maximizing (2) using the grid search
proposed in Section 2.1 is infeasible. However, we can use the Metropolis algo-
rithm similar to that proposed for a patient-specific utility function. A patient-
specific utility function can be accommodated by setting u(y1, . . . , yK;x, θ) =∑K−1
k=1 expit(x
⊺θk)y1+
{
1−∑K−1k=1 expit(x⊺θk)} yK for a vector θ = (θ⊺1 , . . . , θ⊺K−1)⊺
and maximizing the pseudo-likelihood using the Metropolis algorithm.
To examine the performance of the proposed method in the presence of more
than two outcomes, we use the following generative model. As before, let X =
(X1, . . . , X5)
⊺ be independent normal random variables with mean 0 and standard
deviation 0.5. Let ǫ1, ǫ2, and ǫ3 be independent normal random variables with
mean 0 and standard deviation 0.5. Given treatment assignment, outcomes are
generated according to Y1 = A(4X1 − 2X2 + 2) + ǫ1, Y2 = A(2X1 − 4X2 − 2) + ǫ2,
and Y3 = 1 + A(X1 + X2 + 1)ǫ3. For a fixed ω = (ω1, ω2) and fixed ρ ∈ [0, 1],
treatment assignment is made according to Pr {A = doptω (x)|X = x} = ρ.
We set ω1 = 0.2, ω2 = 0.4, and ρ = 0.6, 0.8. Table 10 contains parame-
ter estimates averaged across 500 replications along with standard deviations (in
parentheses) across replications. The error rate is the proportion of samples in a
testing set that were assigned the optimal treatment by the estimated policy. Ta-
ble 11 contains estimated values (calculated by generating an independent testing
set following the same generative model but with decisions made according to each
policy) of the optimal policy, a policy where the utility function is estimated (the
proposed method), policies estimated to maximize each outcome individually, and
standard of care. The proposed method results in values close to the true opti-
mal in large samples and larger than maximizing each individual outcome across
sample sizes.
Misspecified Model for the Utility Function
In this section, we demonstrate that the proposed method achieves reasonable
performance even in the presence of a misspecified model for the utility function.
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n ρ ω̂1,n ω̂2,n ρ̂n Error rate
100 0.60 0.21 (0.16) 0.34 (0.20) 0.63 (0.07) 0.15 (0.11)
0.80 0.21 (0.07) 0.42 (0.09) 0.81 (0.04) 0.04 (0.03)
200 0.60 0.21 (0.13) 0.40 (0.17) 0.62 (0.04) 0.11 (0.09)
0.80 0.21 (0.04) 0.41 (0.06) 0.80 (0.03) 0.03 (0.02)
300 0.60 0.21 (0.12) 0.39 (0.16) 0.62 (0.03) 0.09 (0.08)
0.80 0.20 (0.03) 0.41 (0.04) 0.80 (0.02) 0.02 (0.01)
500 0.60 0.21 (0.09) 0.41 (0.12) 0.61 (0.02) 0.06 (0.05)
0.80 0.20 (0.02) 0.40 (0.03) 0.80 (0.02) 0.01 (0.01)
Table 10: Estimation results for simulations where utility and probability of opti-
mal treatment are fixed, with three outcomes.
n ρ Optimal Estimated utility Y1 only Y2 only Y3 only Standard of care
100 0.60 1.38 (0.04) 1.28 (0.15) 1.09 (0.06) 1.00 (0.06) 0.62 (0.10) 0.59 (0.14)
0.80 1.39 (0.04) 1.37 (0.06) 1.09 (0.06) 1.00 (0.06) 0.62 (0.11) 0.99 (0.13)
200 0.60 1.38 (0.04) 1.32 (0.12) 1.09 (0.06) 1.00 (0.06) 0.62 (0.08) 0.60 (0.10)
0.80 1.39 (0.04) 1.38 (0.05) 1.09 (0.05) 1.00 (0.06) 0.62 (0.09) 0.98 (0.09)
300 0.60 1.38 (0.04) 1.34 (0.10) 1.09 (0.06) 1.00 (0.06) 0.63 (0.08) 0.60 (0.08)
0.80 1.38 (0.04) 1.39 (0.05) 1.10 (0.06) 1.00 (0.06) 0.63 (0.08) 0.99 (0.07)
500 0.60 1.39 (0.04) 1.36 (0.07) 1.09 (0.05) 1.00 (0.06) 0.62 (0.07) 0.60 (0.06)
0.80 1.39 (0.04) 1.38 (0.05) 1.10 (0.06) 1.00 (0.06) 0.63 (0.07) 0.99 (0.06)
Table 11: Value results for simulations where utility and probability of optimal
treatment are fixed, with three outcomes.
Let X, Y , and Z be generated as above. Let the true underlying utility function
be u(y, z;x, θ) = ω(x; θ)y + {1− ω(x; θ)} z, where ω(x; θ) = expit (1 + x21 + x⊺θ0)
with θ0 = (−0.5, 0, 0, 1, 0.5)⊺. The misspecified model fit to estimate the utility
function contained only an intercept, X1, X2, X3, and X4. Therefore, these sim-
ulations represent the setting where one important covariate and a squared term
for one covariate are omitted from the model for the utility function. Treatment
was assigned according to Pr {A = doptω (x)|X = x} = expit (0.5 + x1). Table 12
contains the estimated value when the model for the utility function is correctly
specified and when the model is incorrectly specified, along with the value of the
true optimal policy and the standard of care. The proposed method produces
comparable results regardless of whether the utility function is misspecified or
not.
Table 13 contains results for the same model misspecification, but where the
true utility function is ω(x; θ) = expit (1 + 4x21 + x
⊺θ0) with θ0 = (−0.5, 0, 0, 1, 4)⊺,
i.e., the coefficients for the components that are left out of the misspecified model
are larger. When the coefficients of the components left out of the utility function
model are larger, the proposed method produces better results when the model is
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n Optimal Correct Misspecified Standard of Care
100 1.86 (0.07) 1.61 (0.21) 1.64 (0.20) 0.59 (0.23)
200 1.85 (0.07) 1.68 (0.16) 1.69 (0.17) 0.57 (0.16)
300 1.86 (0.07) 1.72 (0.13) 1.74 (0.13) 0.57 (0.13)
500 1.86 (0.07) 1.77 (0.10) 1.76 (0.11) 0.58 (0.10)
Table 12: First simulation results with a misspecified model for the utility function.
n Optimal Correct Misspecified Standard of Care
100 2.11 (0.08) 1.63 (0.28) 1.64 (0.23) 0.69 (0.26)
200 2.11 (0.08) 1.76 (0.22) 1.68 (0.18) 0.67 (0.18)
300 2.10 (0.07) 1.84 (0.19) 1.70 (0.16) 0.68 (0.15)
500 2.10 (0.08) 1.88 (0.16) 1.73 (0.15) 0.67 (0.12)
Table 13: Second simulation results with a misspecified model for the utility func-
tion.
correctly specified. However, even in the presence of model misspecification, the
proposed method produces results that improve upon the standard of care.
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